While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...

Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...

Incyte today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

What Is Lunsumio Velo, and Why Does It Matter? Lunsumio Velo (mosunetuzumab-axgb) is a new under-the-skin (subcutaneous) injection version of the anticancer medicine Lunsumio intravenous infusion. The ...

– Approval supported by data demonstrating compelling complete response rate in third-line or later follicular lymphoma, which typically becomes harder to treat after each relapse – Genentech, a ...

(MENAFN- GlobeNewsWire - Nasdaq) BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( ), an integrated pharmaceutical company maximizing commercial outcomes for oncology ...

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today ...

Dr Kami Maddocks shares highlights from ASH 2025, including how the phase 3 EPCORE FL‑1 trial, adding a bispecific antibody to R2 in second‑line or later follicular lymphoma, showed significantly ...

Detailed price information for Corvus Pharma Com (CRVS-Q) from The Globe and Mail including charting and trades.

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab ...